Literature DB >> 11412285

Oral gavage of oleoyl-oestrone has a stronger effect on body weight in male Zucker obese rats than in female.

M M Grasa1, M Esteve, R M Masanés, P Yubero, M Blay, J López-Martí, C Cabot, R Vilà, J A Fernández-López, X Remesar, M Alemany.   

Abstract

This study was carried out to determine the effect of sex and oral administration of oleoyl-oestrone on body weight of 12-week-old female and male Zucker obese (fa/fa) rats initially weighing 350-380 g and 405-420 g, respectively. The rats were maintained in standard conditions and given a daily oral gavage of 0.2 ml oleoyl-oestrone dissolved in sunflower oil at a dose of 10 micromol/kg/day for 10 days, and their body weight and food intake was monitored. They were then killed, and their carcass composition (water, lipid, protein and total energy), liver lipids and glycogen and plasma chemistry, insulin, free and total oestrone were measured. Oral administration of oleoyl-oestrone via gavage resulted in significant losses of fat, energy and-ultimately-weight. Treatment with oleoyl-oestrone decreased food intake; the energy expenditure was kept close to that of controls at the expense of internal fat stores. Nevertheless, body protein and plasma metabolite homeostasis were preserved. The slimming effects were more marked in males than in females. Treatment increased circulating acyl-oestrone and reduced to normal levels the high insulin observed in controls. Treatment of genetically obese rats with a daily oral gavage of oleoyl-oestrone resulted in the loss of fat reserves with little modification of other metabolic parameters, except for lower plasma glucose and insulin levels. The results suggest that oleoyl-oestrone, in addition to its slimming effects may be effective as an antidiabetic agent in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11412285     DOI: 10.1046/j.1463-1326.2001.00143.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  8 in total

1.  Modulation of muscle UCP expression by oleoyl-estrone in the rat.

Authors:  P Yubero; R M Masanés; J A Fernández-López; X Remesar; M Alemany
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

Review 2.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Estrogens and Body Weight Regulation in Men.

Authors:  Katya B Rubinow
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

4.  Effect of oleoyl-estrone treatment on the expression of beta1- beta2- and beta3-adrenoreceptors in rat adipose tissues.

Authors:  C Cabot; M del Mar Grasa; J A Fernández-López; M Alemany
Journal:  Mol Cell Biochem       Date:  2001-05       Impact factor: 3.396

5.  Intestinal oleoyl-estrone esterase activity in the Wistar rat.

Authors:  M Serrano-Muñoz; M M Grasa; D González-Martínez; C Cabot; J A Fernández-López; M Alemany
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

6.  Treatment of rats with a self-selected hyperlipidic diet, increases the lipid content of the main adipose tissue sites in a proportion similar to that of the lipids in the rest of organs and tissues.

Authors:  María Del Mar Romero; Stéphanie Roy; Karl Pouillot; Marisol Feito; Montserrat Esteve; María Del Mar Grasa; José-Antonio Fernández-López; Marià Alemany; Xavier Remesar
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

7.  Circulating oestradiol determines liver lipid deposition in rats fed standard diets partially unbalanced with higher lipid or protein proportions.

Authors:  Laia Oliva; Marià Alemany; José-Antonio Fernández-López; Xavier Remesar
Journal:  Br J Nutr       Date:  2021-11-15       Impact factor: 4.125

Review 8.  Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy.

Authors:  Dante J Merlino; Erik S Blomain; Amanda S Aing; Scott A Waldman
Journal:  J Clin Med       Date:  2014-07-15       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.